Trial Profile
A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda; Takeda Development Centre Europe
- 14 Apr 2024 This study has been completed in Lithuania, according to European Clinical Trials Database record.
- 15 Mar 2023 Status changed from not yet recruiting to recruiting.
- 15 Feb 2023 Planned initiation date changed from 30 Jan 2023 to 27 Feb 2023.